Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study

Atogepant, an oral calcitonin gene‐related peptide receptor antagonist, is approved for the preventive treatment of migraine. Atogepant is a substrate of P‐glycoprotein (P‐gp), breast cancer resistance protein, organic anion transporting polypeptide transporters, and cytochrome P450 (CYP)3A4 and 2D6...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology in drug development 2024-08, Vol.13 (8), p.930-937
Hauptverfasser:	Boinpally, Ramesh, Borbridge, Lisa, Wangsadipura, Veronica
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Area Under Curve atogepant ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism CGRP receptor antagonist CYP2D6 Cytochrome P-450 CYP2D6 Inhibitors - administration & dosage Cytochrome P-450 CYP2D6 Inhibitors - adverse effects Cytochrome P-450 CYP2D6 Inhibitors - pharmacokinetics Cytochrome P-450 CYP2D6 Inhibitors - pharmacology Drug Interactions drug‐drug interactions Female Healthy Volunteers Humans Male Middle Aged migraine Pharmacokinetics P‐gp quinidine Quinidine - administration & dosage Quinidine - adverse effects Quinidine - analogs & derivatives Quinidine - pharmacokinetics Quinidine - pharmacology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!